.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,419,960

« Back to Dashboard

Claims for Patent: 6,419,960

Title: Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Abstract:The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Inventor(s): Krishnamurthy; Thinnayam N. (Scarborough, CA), Darke; Andrew (Newmarket, CA)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:09/465,159
Patent Claims: 1. An oral controlled release formulation which provides a rapid onset of therapeutic effect and a rapid drop in plasma concentration after a prolonged period of therapeutic effect, comprising a plurality of substrates comprising a portion of the effective dose of a drug in immediate release form, a hydrophobic material coated onto the surface of said substrates in an amount sufficient to retard the release of said drug, an enteric coating applied over said hydrophobic coating in an amount sufficient to substantially delay the release of said drug from said substrate until after said formulation passes through the stomach, the formulation further comprising the remaining portion of said drug in immediate release form; wherein the oral dosage form provides a time to maximum plasma concentration at about 0.5 to about 4 hours after oral administration and wherein the duration of effect provided by the drug contained in the formulation falls below effective plasma concentrations at about 8 to about 12 hours after oral administration.

2. The formulation of claim 1, wherein said remaining portion of said drug is applied to said substrates over said enteric coating.

3. The formulation of claim 1, wherein a unit dose of said plurality of substrates are contained within a gelatin capsule, and said remaining portion of said drug is also contained within said gelatin capsule in a form selected from the group consisting of an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, and as a coating applied onto the surface of said enteric coated substrates.

4. The formulation of claim 1, wherein said hydrophobic material comprises a plasticized aqueous dispersion of an acrylic polymer which is sprayed onto the surface of said substrates.

5. The formulation of claim 4, wherein said substrates are subjected to oven curing at a temperature above the glass transition temperature of the plasticized acrylic polymer at a temperature from about 40 to about 50.degree. C. for a time period of at least about 12 hours prior to the application of said enteric coating.

6. The formulation of claim 1, which provides a peak plasma concentration of the drug which is from about 1.0 to about 2.0 times the plasma concentration of the drug provided by the formulation at about 9 hours after oral administration.

7. The formulation of claim 1, wherein the oral dosage form provides a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration.

8. The formulation of claim 6, wherein the peak plasma concentration is from about 1.0 to about 1.7 times the plasma concentration of drug provided by the formulation at about 9 hours after oral administration.

9. The formulation of claim 6, wherein the duration of effect provided by the drug contained in the oral dosage form falls below effective plasma concentrations at about 8 to about 10 hours after oral administration.

10. The formulation of claim 9, which provides a "square wave" plasma profile.

11. The formulation of claim 9, which provides an in-vitro dissolution as follows:

12. A method for preparing an oral controlled release formulation which provides a rapid onset of therapeutic effect and a rapid drop in plasma concentration after a prolonged period of therapeutic effect, comprising preparing a plurality of substrates comprising a portion of the effective dose of a drug in immediate release form by spraying a solution of the drug onto said substrates; applying a hydrophobic material to said substrates in an amount to retard the release of said drug; applying an enteric coating over said hydrophobic coating in an amount sufficient to substantially delay the release of said drug from said substrate until after said formulation passes through the stomach; applying an immediate release overcoat of said drug onto said enteric coated substrates; wherein the oral dosage form provides a time to maximum plasma concentration at about 0.5 to about 4 hours after oral administration and wherein the duration of effect provided by the drug contained in the formulation falls below effective plasma concentrations at about 8 to about 12 hours after oral administration.

13. The method of claim 12, wherein the hydrophobic material is derived from an aqueous dispersion of plasticized acrylic polymer, said hydrophobic material being subjected to oven curing at a temperature above the glass transition temperature of the plasticized acrylic polymer at a temperature from about 40 to about 50.degree. C. for a time period of about 12 to about 24 hours, prior to the application of said enteric coating.

14. The method claim 12, wherein said enteric coating is derived from a solution of acrylic/methacrylic copolymers dispersion, triethyl citrate and talc.

15. The method of claim 12, wherein formulation provides an in-vitro dissolution as follows:

16. The method of claim 15, wherein said formulation provides a time to maximum plasma concentration of the drug at about 0.5 to about 4 hours after oral administration and a peak plasma concentration of the drug which is from about 1.0 to about 2.0 times the plasma concentration of the drug provided by the formulation at about 9 hours after oral administration.

17. The method of claim 15, wherein the plasma concentration of the drug when administered to a human patient falls below effective plasma concentrations at about 8 to about 12 hours after oral administration.

18. The method of claim 17, wherein the formulation provides a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc